LDLR's Hidden Splice Switch — When Silent Mutations Aren't Silent
The low-density lipoprotein receptor (LDLR) pulls cholesterol-carrying LDL particles out of the
bloodstream and into liver cells for clearance. Most people know that rare LDLR mutations cause
familial hypercholesterolemia, a severe inherited condition of massively elevated cholesterol.
But LDLR is also shaped by a network of common regulatory variants that subtly tune how much
functional receptor your liver produces — variants that don't alter the protein sequence at all,
yet still affect cholesterol levels measurably.
rs5925 is one such variant. Located in exon 13 of LDLR, it produces a synonymous change
(c.1959T>C, p.Val653=): both alleles encode valine, so the protein sequence is identical
regardless of which allele you carry. Yet [multiple population studies across Chilean, Egyptian,
South Indian, and Chinese cohorts | Rojas 2019; Alsabbagh 2022; Jha 2019; Wang 2023] have
associated the C allele with higher LDL cholesterol and cardiovascular risk. The molecular
explanation involves mRNA splicing — a key step in gene regulation that occurs after
transcription but before the protein is made.
The Mechanism
Synonymous variants can profoundly affect gene output by disrupting exonic splicing enhancers
(ESEs) | Short RNA sequences within exons that signal to the spliceosome to include the exon in
the mature mRNA. If an ESE is disrupted, the
spliceosome may skip the exon, producing a truncated or non-functional protein.
The Lee et al. 2014 minigene study | Lee JD et al. Mutual effect of rs688 and rs5925 in
regulating low-density lipoprotein receptor splicing. DNA Cell Biol, 2014
demonstrated that rs5925 and the nearby synonymous variant rs688 (exon 12) jointly control LDLR
exon splicing efficiency. Using minigene constructs in human cell lines and confirmed in
leukocyte RNA from patients, they measured how efficiently exon 12 and exon 13 were retained in
mature LDLR mRNA across all four possible haplotype combinations:
- rs688-C / rs5925-C: 79.6% splicing efficiency (highest)
- rs688-C / rs5925-T: 76.7%
- rs688-T / rs5925-C: 69.0%
- rs688-T / rs5925-T: 68.5% (lowest)
rs5925 accounts for approximately 5.4% of splicing efficiency difference when rs688 carries the
C allele. Critically, rs688-T (itself associated with reduced exon 12 inclusion) and rs5925-C
rarely co-occur in high-splicing haplotypes in the populations where C-allele LDL elevation is
observed — the predominant clinical haplotype combines rs688-T with rs5925-C, creating the TC
combination with 69% efficiency versus the protective CC combination at 79.6%. This haplotype
context explains why the population-level C allele effect on LDL is adverse despite rs5925-C
appearing more efficient when paired with rs688-C.
The Evidence
Clinical evidence from multiple independent cohorts consistently links the C allele with higher
LDL cholesterol. In a study of 178 healthy subjects from northern Chile | Rojas C et al.
JCLA, 2019, individuals carrying at least one T
allele had significantly lower total cholesterol, triglycerides, and LDL-C than CC homozygotes
(p<0.05). The distribution in this Latin American population (CC 19%, CT 53%, TT 28%) closely
matches Hardy-Weinberg predictions for a C allele frequency of ~45-53%, consistent with global
gnomAD data.
In a case-control study of 400 South Indians | Jha CK et al. Med Sci, 2019
(200 coronary artery disease patients, 200 matched controls), the heterozygous genotype at
rs5925 was significantly protective against CAD (OR=0.45, 95% CI 0.27-0.75, p=0.002),
demonstrating that the T allele confers cardiovascular protection beyond lipid levels alone.
An Egyptian study of 100 lupus nephritis patients | Alsabbagh YA et al. Arch Rheumatol, 2022
found the C allele significantly more prevalent in patients than healthy controls (60% vs 45%,
p=0.003), with CC genotype carriers showing higher atherogenic index and LDL/HDL ratios. TT
and CT genotypes showed significantly lower TC, TG, and LDL-C than CC homozygotes.
A 2023 Chinese adolescent study | Wang J et al. Int J Mol Sci, 2023
involving 709 students confirmed that male C allele carriers had elevated total cholesterol and
LDL-C compared to TT homozygotes in the control group.
Notably, one Chilean pharmacogenomics study | Lagos J et al. Int J Mol Sci, 2015
examining atorvastatin response in 139 hypercholesterolemic subjects found no significant
association between rs5925 and statin-induced LDL reduction (p=0.576). This suggests the
variant's effect on LDLR expression levels does not meaningfully alter the pharmacodynamic
response to statins, which primarily works through a separate mechanism (inhibiting cholesterol
synthesis and upregulating LDLR protein quantity rather than splicing efficiency).
Practical Actions
For CC homozygotes, the elevated LDL risk is modest in absolute terms — this is not a
pathogenic variant, and the LDL difference between genotypes is in the range of a few mg/dL
to perhaps 10-15 mg/dL in studies with the largest effects. The practical implication is
attentiveness: more frequent LDL monitoring, prompt action when cholesterol trends upward, and
consideration of dietary and pharmaceutical interventions earlier rather than later.
Dietary strategies with the strongest LDL-lowering evidence independent of genotype — soluble
fiber, plant sterols, reduced saturated fat — are particularly relevant for CC carriers since
their genetic baseline LDLR efficiency is lower. These interventions enhance cholesterol
clearance through mechanisms that can partially compensate for reduced splicing efficiency.
Because statin response does not appear to track with rs5925 genotype, standard lipid management
guidelines apply to CC homozygotes who require pharmacotherapy.
Interactions
rs5925 functions within a two-SNP regulatory module with rs688. The splicing efficiency of LDLR
exon transcripts is jointly determined by both variants, with rs688 being the dominant partner
(accounting for ~9.4% vs rs5925's ~5.4% of the variation in splicing efficiency). Together,
the rs688-T / rs5925-C haplotype produces the lowest splicing output. Individuals carrying both
risk alleles (rs688-T and rs5925-C) have the most reduced LDLR mRNA splicing efficiency and
may face compounded LDL-raising effects.
This variant also operates in the context of the broader LDLR regulatory landscape. rs6511720
(intron 1) modulates LDLR transcription through a sterol response element — it affects how much
mRNA is produced before splicing even occurs. A CC homozygote at rs5925 who also carries the
rs6511720 GG genotype (common, lower-expression) would experience a compounded reduction in
functional LDLR output: reduced transcription AND reduced splicing efficiency. Conversely,
rs6511720-T carriers (enhanced transcription) may partially offset the splicing inefficiency
of the rs5925-C allele by producing more total transcript.
Alla genotyper
Reference allele — normal LDLR splicing efficiency and standard LDL clearance
You carry two copies of the T allele at rs5925, the GRCh38 reference allele associated with standard or slightly enhanced LDLR splicing efficiency in population studies. About 32% of people globally share the TT genotype. Multiple studies across diverse populations — Chilean, Egyptian, South Indian, and Chinese cohorts — consistently show TT carriers have lower total cholesterol, LDL-C, and triglycerides compared to CC homozygotes, and reduced cardiovascular disease risk compared to C allele carriers. Your LDLR mRNA is processed efficiently, producing adequate receptor protein for normal cholesterol clearance. No specific intervention is indicated based on this genotype.
Heterozygous — moderately reduced LDLR splicing efficiency, mildly elevated LDL tendency
You carry one copy of the C allele at rs5925. About 49% of people globally share this heterozygous genotype, making CT the most common genotype in most populations. Population studies show that C allele carriers have modestly higher LDL cholesterol and total cholesterol compared to TT homozygotes. The effect is codominant, meaning one C allele produces an intermediate phenotype between TT (lowest LDL) and CC (highest LDL). In the South Indian coronary artery disease study, the heterozygous genotype was significantly protective (OR=0.45 vs CC) — suggesting that even one T allele is meaningfully beneficial compared to homozygous CC. Your LDLR splicing is slightly less efficient than TT carriers in the dominant haplotype context, but the effect at this heterozygous level is modest in absolute terms.
Two C alleles — reduced LDLR splicing efficiency, consistently higher LDL-C in population studies
You carry two copies of the C allele at rs5925. About 19% of people globally share the CC genotype. Multiple independent population studies consistently show CC homozygotes have the highest LDL cholesterol, total cholesterol, and atherogenic lipid ratios among the three rs5925 genotypes. In an Egyptian cohort, the C allele was significantly more prevalent in lupus nephritis patients with dyslipidemia than in healthy controls (60% vs 45%, p=0.003), and CC genotype carriers had significantly higher total cholesterol, triglycerides, LDL-C, and atherogenic index than TT or CT carriers. In a South Indian CAD case-control study, carrying at least one T allele was associated with a 55% reduced odds of coronary artery disease compared to CC homozygotes. A Chilean cohort confirmed lower LDL-C, triglycerides, and total cholesterol in T allele carriers compared to CC. The underlying mechanism involves reduced LDLR mRNA splicing efficiency. When paired with the common rs688-T allele (which itself reduces splicing), your rs5925-C allele further reduces efficient exon processing, lowering the proportion of functional LDLR transcripts and the number of LDL receptors on your liver cells.